Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0002044377-26-000002
Filing Date
2026-05-18
Accepted
2026-05-18 20:20:01
Documents
2
X0202

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 10242
2 JOINT FILING AGREEMENT ex-99-05192026_120500.htm EX-99.1 3459
  Complete submission text file 0002044377-26-000002.txt   15359
Mailing Address 51 SLEEPER STREET BOSTON MA 02210
Business Address 51 SLEEPER STREET BOSTON MA 02210 (212) 841-1000
Odyssey Therapeutics, Inc. (Subject) CIK: 0001882782 (see all company filings)

EIN.: 863384382 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-95704 | Film No.: 26995603
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 2200 SAND HILL ROAD MENLO PARK CA 94025
Business Address 2200 SAND HILL ROAD MENLO PARK CA 94025 650-234-8300
Lightspeed Venture Partners XV-B (Ignite), L.P. (Filed by) CIK: 0002044377 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G